TC-510
PreclinicalBiologic
TC-510 is one of 49 biologic programs targeting Mesothelioma. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
86 competitors in Mesothelioma
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Alimta
EEagle Vision Pharmaceutical Corp.
Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Tecentriq
RochePhase 3
Alimta
GGynecologic Oncology Group
Phase 3
Ofev
Boehringer IngelheimPhase 3
Adriamycin
GGynecologic Oncology Group
Phase 3
Tomudex
NNanjing Chia-tai Tianqing Pharmaceutical
Phase 3
Standard Chemotherapy
RochePhase 3
Keytruda
Merck & Co.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TC-510. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- TTCR2 Therapeutics